Drug Trial Radar · NCT07093333
A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 15, 2026
Primary completion
Nov 30, 2027
Study completion May 30, 2028
Sponsor
- Lead sponsor
- Arialys Australia Pty LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Arialys Therapeutics; Seoul National University Hospital
- First posted
- Jul 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability, preliminary efficacy and pharmacokinetics (PK) of ART5803 in adult participants with a confirmed diagnosis of anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis (ANRE) or anti-NMDAR autoantibody-associated psychiatric disease
Conditions
- Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)
- Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease
- Autoimmune Encephalitis
Interventions
ART5803Drug
A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor. 1. Sentinel participants: 30 mg/kg 2. Subsequent participants: up to 60 mg/kg 3. Schedule: Q1W for 4 doses then Q2W for 4 doses
ART5803-Cohort DDrug
A monovalent (one-armed) antibody, that binds to the NTD of the NMDAR NR1 subunit without causing NMDAR inhibition, activation, or receptor internalization, while simultaneously blocking the ability of the pathogenic anti-NMDAR autoantibodies to bind to the receptor. Participants receive ART5803 by intravenous infusion once a week for 4 weeks, then every 2 weeks for 8 weeks, for a total of 8 doses. Sentinel participants receive 30 mg per kg. Additional participants may receive up to 60 mg per kg based on Safety Review Committee guidance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
- To assess the safety and tolerability of ART5803Time frame: 26 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul National University Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.